Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 11/20 | 0.54 |
| ▸ | AVPR1B | P47901 | 9/20 | 0.54 |
| ▸ | AVPR2 | P30518 | 10/20 | 0.46 |
| ▸ | OXTR | P30559 | 3/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6203310 | 0.83 | AVPR1A (0.60) | AVPR1AAVPR1BAVPR2OXTR | |
| SCHEMBL6202773 | 0.81 | AVPR1A (0.55) | AVPR1AAVPR1BAVPR2OXTR | |
| SCHEMBL1346034 | 0.81 | SLC22A12 (0.61) | AVPR1AAVPR2OXTRSLC22A12SMN1; SMN2 | |
| SCHEMBL4835299 | 0.80 | AVPR1A (0.54) | AVPR1AAVPR1BAVPR2OXTR | |
| SCHEMBL5230491 | 0.75 | AVPR2 (0.57) | AVPR1AAVPR2SLC22A12KDM4ESMN1; SMN2 | |
| SCHEMBL6985203 | 0.74 | AVPR1A (0.61) | AVPR1AAVPR1BAVPR2OXTR | |
| SCHEMBL18373754 | 0.73 | NOTUM (0.55) | SLC22A12NPC1ALDH1A1HPGDRAB9A | |
| SCHEMBL4146200 | 0.72 | AVPR1A (0.68) | AVPR1AAVPR1BAVPR2OXTRHPGD | |
| SCHEMBL7020907 | 0.72 | AVPR1A (0.63) | AVPR1AAVPR1BAVPR2 | |
| SCHEMBL5232249 | 0.72 | SLC22A12 (0.46) | AVPR1AAVPR2OXTRSLC22A12SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275026-A1 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | FERRING B.V. | 2008-11-06 | — | — | US | disclosed |
| US-7407949-B2 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | FERRING B.V. (NL) | 2008-08-05 | — | — | US | disclosed |
| EP-1294698-B1 | FUSED AZEPINE DERIVATIVES AND THEIR USE AS ANTIDIURETIC AGENTS | FERRING BV (NL) | 2007-08-01 | — | — | EP | disclosed |
| US-7176195-B2 | Fused azepine derivatives and their use as antidiuretic agents | FERRING BV (NL) | 2007-02-13 | — | — | US | disclosed |
| US-20060166971-A1 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | FERRING B.V. (NL) | 2006-07-27 | — | — | US | disclosed |
| EP-1592693-A1 | BENZAMIDE DERIVATIVES AS OXYTOCIN AGONISTS AND VASOPRESSIN ANTAGONISTS | Ferring B.V. (NL) | 2005-11-09 | — | — | EP | disclosed |
| EP-1399436-B1 | OXYTOCIN AGONISTS | FERRING BV (NL) | 2005-03-16 | — | — | EP | disclosed |
| US-20050032777-A1 | Diazacycloalkanes as oxytocin agonists | FEERING B.V. (NL) | 2005-02-10 | — | — | US | disclosed |
| US-20040235753-A1 | Oxytocin agonists | PITT GRAY ROBERT WILLIAM (GB) | 2004-11-25 | — | — | US | disclosed |
| WO-2004072083-A1 | BENZAMIDE DERIVATIVES AS OXYTOCIN AGONISTS AND VASOPRESSIN ANTAGONISTS | FERRING B.V. (NL) | 2004-08-26 | — | — | WO | disclosed |
| EP-1449844-A1 | benzamide derivatives as oxytocin agonists and vasopressin antagonists | FERRING B.V. (NL) | 2004-08-25 | — | — | EP | disclosed |
| EP-1421087-A1 | DIAZACYCLOALKANES AS OXYTOCIN AGONISTS | FERRING B.V. (NL) | 2004-05-26 | — | — | EP | disclosed |
| US-20040038962-A1 | Fused azepine derivatives and their use as antidiuretic agents | VANTIA LIMITED (GB) | 2004-02-26 | — | — | US | disclosed |
| WO-2003016316-A1 | DIAZACYCLOALKANES AS OXYTOCIN AGONISTS | FERRING B.V. (NL) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003016316-A1 | DIAZACYCLOALKANES AS OXYTOCIN AGONISTS | FERRING B.V. (NL) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032777-A1 | Diazacycloalkanes as oxytocin agonists | OXTR, GNRHR, KISS1R | AVPR1A 8/4885AVPR1B 11/4885AVPR2 15/4885 |
| US-20080275026-A1 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | AVPR1A, AVPR2, AVPR1B | AVPR1A 1/4885AVPR1B 3/4885AVPR2 2/4885 |
| US-20060166971-A1 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists | AVPR1A, AVPR2, AVPR1B | AVPR1A 1/4885AVPR1B 3/4885AVPR2 2/4885 |
| US-20040235753-A1 | Oxytocin agonists | OXTR, GNRHR, PRLHR | AVPR1A 7/4885AVPR1B 11/4885AVPR2 10/4885 |
| US-20040038962-A1 | Fused azepine derivatives and their use as antidiuretic agents | AVPR2, AVPR1A, AVPR1B | AVPR1A 2/4885AVPR1B 3/4885AVPR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.